User: OPTILAB CHU Sainte-Justine
Hematologists are frequently called upon to evaluate patients for potential bleeding or clotting disorders. However, in many cases, no definitive cause is identified. This lack of a clear diagnosis does not imply that the patient is free of a disorder but rather highlights the limitations of our current diagnostic tools. Consequently, patients are often assigned placeholder diagnoses that acknowledge the uncertainty surrounding the cause of their symptoms—a situation that can be frustrating for both patients and clinicians.
Without a clear diagnosis, critical questions remain unanswered: What is the most effective treatment? How might the condition progress over time? What is the likelihood that a family member could be affected by the same disorder? These uncertainties leave patients and their families in a state of limbo.
We do know, however, that variations in the same gene can sometimes result in bleeding in one patient and clotting in another. For patients suspected of having such genetic issues, comprehensive genetic testing offers the best chance of reaching a definitive diagnosis. This approach is not only more thorough than certain international tests but also more cost-effective. By identifying the genetic basis of these disorders, we can improve patient education, tailor treatments, and provide more accurate prognoses, ultimately enhancing care for these individuals.